• Consensus Rating: Moderate Buy
  • Consensus Price Target: $317.25
  • Forecasted Upside: 39.30%
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 10 Buy Ratings
  • 0 Strong Buy Ratings
▲ +5.66 (2.55%)

This chart shows the closing price for PEN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Penumbra Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PEN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PEN

Analyst Price Target is $317.25
▲ +39.30% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Penumbra in the last 3 months. The average price target is $317.25, with a high forecast of $376.00 and a low forecast of $240.00. The average price target represents a 39.30% upside from the last price of $227.75.

This chart shows the closing price for PEN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Moderate Buy

The current consensus among 12 investment analysts is to moderate buy stock in Penumbra. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/3/2023Piper SandlerLower TargetOverweight ➝ Overweight$335.00 ➝ $250.00Low
11/3/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$265.00 ➝ $240.00Low
10/2/2023CitigroupLower TargetBuy ➝ Buy$390.00 ➝ $320.00Low
9/19/2023Piper SandlerReiterated RatingOverweight ➝ Overweight$335.00Low
9/6/2023Morgan StanleyInitiated CoverageEqual Weight$265.00Low
8/17/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$349.00Low
8/2/2023Canaccord Genuity GroupLower TargetBuy ➝ Buy$351.00 ➝ $322.00Low
8/2/2023Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$320.00 ➝ $337.00Low
8/2/2023Truist FinancialLower TargetBuy ➝ Buy$370.00 ➝ $345.00Low
8/2/2023BTIG ResearchLower Target$351.00 ➝ $308.00Low
7/19/2023Truist FinancialBoost Target$350.00 ➝ $370.00Low
7/18/2023Robert W. BairdInitiated CoverageOutperform$375.00Low
7/17/2023BTIG ResearchBoost Target$328.00 ➝ $351.00Low
7/12/2023Royal Bank of CanadaBoost Target$303.00 ➝ $349.00Low
7/10/2023CitigroupBoost Target$325.00 ➝ $390.00Low
6/26/2023Deutsche Bank AktiengesellschaftBoost Target$325.00 ➝ $376.00Low
6/5/2023BTIG ResearchBoost Target$312.00 ➝ $328.00Low
5/24/2023Piper SandlerBoost Target$300.00 ➝ $335.00Low
5/18/2023Truist FinancialBoost Target$320.00 ➝ $350.00Low
5/3/202358.comReiterated RatingMaintainsLow
5/3/2023Deutsche Bank AktiengesellschaftBoost Target$297.00 ➝ $325.00Low
5/3/2023Wells Fargo & CompanyBoost Target$291.00 ➝ $320.00Low
5/3/2023Royal Bank of CanadaBoost Target$289.00 ➝ $303.00Low
5/3/2023BTIG ResearchBoost Target$301.00 ➝ $312.00Low
5/3/2023Piper SandlerBoost Target$285.00 ➝ $300.00Low
4/17/2023BTIG ResearchBoost Target$279.00 ➝ $301.00Low
4/3/2023CitigroupBoost TargetBuy$303.00 ➝ $325.00Low
3/29/2023Needham & Company LLCDowngradeBuy ➝ HoldLow
2/27/2023CitigroupBoost TargetBuy$270.00 ➝ $303.00Low
2/24/2023Canaccord Genuity GroupBoost TargetBuy$246.00 ➝ $286.00Low
2/24/2023Needham & Company LLCBoost TargetBuy$235.00 ➝ $300.00Low
2/7/2023Deutsche Bank AktiengesellschaftBoost TargetBuy$250.00 ➝ $297.00Low
2/1/2023JPMorgan Chase & Co.Boost TargetOverweight$254.00 ➝ $285.00Low
1/31/2023Truist FinancialBoost Target$255.00 ➝ $284.00Low
1/30/2023BTIG ResearchBoost TargetBuy$240.00 ➝ $270.00Low
1/30/2023Piper SandlerInitiated CoverageOverweight$275.00Low
1/3/2023Deutsche Bank AktiengesellschaftBoost Target$202.00 ➝ $250.00Low
12/20/2022Truist FinancialBoost TargetBuy$228.00 ➝ $255.00Low
12/12/2022Wells Fargo & CompanyBoost TargetOverweight$225.00 ➝ $255.00Low
12/12/2022CitigroupBoost TargetBuy$212.00 ➝ $270.00Low
12/5/2022BTIG ResearchBoost TargetBuy$204.00 ➝ $240.00Low
11/14/2022Royal Bank of CanadaBoost Target$195.00 ➝ $215.00Low
11/14/2022Truist FinancialBoost Target$200.00 ➝ $228.00Low
11/4/2022Wells Fargo & CompanyLower TargetOverweight$260.00 ➝ $225.00Low
11/4/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$203.00 ➝ $185.00Low
11/4/2022BTIG ResearchLower Target$239.00 ➝ $204.00Low
11/4/2022Needham & Company LLCLower TargetBuy$244.00 ➝ $235.00Low
11/4/2022CitigroupUpgradeNeutral ➝ Buy$217.00 ➝ $212.00N/A
10/26/2022Deutsche Bank AktiengesellschaftBoost Target$163.00 ➝ $202.00Low
10/12/2022Jefferies Financial GroupInitiated CoverageBuy$230.00Low
10/5/2022CitigroupDowngradeBuy ➝ Neutral$170.00 ➝ $217.00Low
9/16/2022BTIG ResearchReiterated RatingBuy$213.00 ➝ $239.00Low
9/13/2022Truist FinancialBoost TargetBuy$180.00 ➝ $230.00Low
9/9/2022Needham & Company LLCUpgradeHold ➝ Buy$244.00Low
8/5/2022Canaccord Genuity GroupLower TargetBuy$244.00 ➝ $189.00Low
7/22/2022Truist FinancialLower Target$180.00Low
7/21/2022Deutsche Bank AktiengesellschaftLower Target$250.00 ➝ $163.00Low
7/18/2022BTIG ResearchLower TargetBuy$272.00 ➝ $213.00Low
7/18/2022Royal Bank of CanadaInitiated CoverageOutperform$195.00Low
5/17/2022CitigroupLower Target$280.00 ➝ $220.00N/A
5/4/2022Wells Fargo & CompanyLower Target$321.00 ➝ $265.00High
5/3/2022William BlairReiterated RatingOutperformHigh
4/19/2022Deutsche Bank AktiengesellschaftInitiated CoverageBuy$250.00High
3/18/2022BTIG ResearchInitiated CoverageBuy$272.00Medium
3/8/2022Needham & Company LLCInitiated CoverageHoldHigh
2/23/2022Truist FinancialLower Target$350.00 ➝ $300.00High
2/23/2022Canaccord Genuity GroupLower Target$335.00 ➝ $244.00High
2/23/2022JPMorgan Chase & Co.Lower TargetOverweight$325.00 ➝ $300.00High
2/23/2022CitigroupLower TargetBuy$300.00 ➝ $280.00High
2/8/2022BTIG ResearchReiterated RatingBuy$272.00Low
9/16/2021Truist FinancialInitiated CoverageBuy$350.00Low
9/15/2021Truist FinancialInitiated CoverageBuy$350.00Low
8/10/2021CitigroupBoost TargetBuy$335.00 ➝ $340.00High
8/10/2021BTIG ResearchBoost TargetBuy$299.00 ➝ $308.00High
6/8/2021Wells Fargo & CompanyReiterated RatingBuyMedium
6/4/2021BTIG ResearchUpgradeNeutral ➝ Buy$291.00High
5/5/2021CitigroupBoost Target$325.00 ➝ $335.00High
5/5/2021Wells Fargo & CompanyBoost TargetOverweight$310.00 ➝ $321.00High
2/24/2021CitigroupBoost TargetBuy$255.00 ➝ $325.00Low
2/24/2021Wells Fargo & CompanyBoost TargetOverweight$260.00 ➝ $310.00Low
12/16/2020Wells Fargo & CompanyLower TargetOverweight$265.00 ➝ $215.00Medium
12/16/2020BTIG ResearchDowngradeBuy ➝ NeutralN/A
10/29/2020Smith Barney CitigroupBoost Target$264.00 ➝ $270.00Medium
10/29/2020Wells Fargo & CompanyBoost TargetOverweight$255.00 ➝ $265.00Low
10/29/2020BTIG ResearchBoost TargetBuy$233.00 ➝ $259.00High
9/29/2020BTIG ResearchInitiated CoverageBuy$233.00Low
9/8/2020Bank of AmericaDowngradeBuy ➝ NeutralMedium
8/4/2020Wells Fargo & CompanyBoost TargetOverweight$205.00 ➝ $255.00Medium
8/4/2020CitigroupBoost TargetBuy$214.00 ➝ $264.00Medium
5/8/2020JPMorgan Chase & Co.Boost TargetOverweight$175.00 ➝ $200.00Low
5/8/2020CitigroupBoost TargetBuy$192.00 ➝ $214.00High
3/30/2020Wells Fargo & CompanyLower TargetOverweight$195.00 ➝ $180.00Medium
3/27/2020CitigroupLower TargetBuy$200.00 ➝ $192.00Low
3/4/2020CitigroupInitiated CoverageBuy$200.00Low
12/4/2019JPMorgan Chase & Co.Boost TargetOverweight$185.00 ➝ $200.00Medium
12/2/2019Royal Bank of CanadaReiterated RatingOutperform$192.00Low
8/7/2019Royal Bank of CanadaSet TargetBuy$174.00Low
8/1/2019Wells Fargo & CompanyBoost TargetOutperform$180.00 ➝ $185.00Low
6/13/2019Bank of AmericaBoost TargetBuy$150.00 ➝ $180.00Low
5/30/2019JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$140.00 ➝ $170.00High
5/21/2019William BlairInitiated CoverageOutperformMedium
4/17/2019HC WainwrightReiterated RatingBuyHigh
(Data available from 12/3/2018 forward)

News Sentiment Rating

0.54 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 10 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
  • 13 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 18 very positive mentions
  • 24 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
  • 13 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
  • 9 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 16 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 10 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 6 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Current Sentiment

  • 6 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Penumbra logo
Penumbra, Inc., together with its subsidiairies, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, SENDit, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System, Lightning, and CAT RX brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and POD (Penumbra Occlusion Device) brand, as well as immersive 3D computer-based technology platform under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
Read More

Today's Range

Now: $227.75
Low: $221.01
High: $229.69

50 Day Range

MA: $215.55
Low: $181.44
High: $247.21

52 Week Range

Now: $227.75
Low: $180.93
High: $348.67


383,440 shs

Average Volume

509,143 shs

Market Capitalization

$8.79 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Penumbra?

The following Wall Street research analysts have issued research reports on Penumbra in the last twelve months: 58.com Inc., BTIG Research, Canaccord Genuity Group Inc., Citigroup Inc., Deutsche Bank Aktiengesellschaft, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Piper Sandler, Robert W. Baird, Royal Bank of Canada, StockNews.com, TheStreet, Truist Financial Co., and Wells Fargo & Company.
View the latest analyst ratings for PEN.

What is the current price target for Penumbra?

12 Wall Street analysts have set twelve-month price targets for Penumbra in the last year. Their average twelve-month price target is $317.25, suggesting a possible upside of 39.3%. Deutsche Bank Aktiengesellschaft has the highest price target set, predicting PEN will reach $376.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $240.00 for Penumbra in the next year.
View the latest price targets for PEN.

What is the current consensus analyst rating for Penumbra?

Penumbra currently has 2 hold ratings and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for PEN.

What other companies compete with Penumbra?

How do I contact Penumbra's investor relations team?

Penumbra's physical mailing address is One Penumbra Place, Alameda CA, 94502. The company's listed phone number is (510) 748-3200 and its investor relations email address is [email protected]. The official website for Penumbra is www.penumbrainc.com. Learn More about contacing Penumbra investor relations.